✦ LIBER ✦

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial

✍ Scribed by Ozden Altundag; Kadri Altundag; Cem Boruban; Yavuz S. Silay; Selahattin Turen

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 48 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21407

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate lacks activity in smal

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein : A Phase II clinical trial

✍ Lee M. Krug; John P. Crapanzano; Christopher G. Azzoli; Vincent A. Miller; Naiye 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Lack of trastuzumab activity in nonsmall

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2 : 39810: A Phase II trial of cancer and leukemia group B

✍ Gerald Clamon; James Herndon; Jeffrey Kern; Ramaswamy Govindan; Jennifer Garst; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Paclitaxel, carboplatin, and topotecan i

Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung carcinoma : A Phase II trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Lisa H. Morrissey; Daniel C. Scullin Jr.; Gerry Ann Houston; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the feasibility, toxicity, and efficacy of a novel three‐drug regimen containing paclitaxel, carboplatin, and topotecan followed by oral etoposide in the first‐line treatment of patients with small cell lung carcinoma. ## METHO